MA

Mark Angelino

Stealth at newco

Greater Boston

Overview 

Mark Angelino is currently serving as the Head of Stealth at a new company in Greater Boston, with a background that includes roles such as Founder and Chief Operating Officer at Generation Bio and Senior Vice President of Pharmaceutical Sciences at bluebird bio. He holds a PhD from MIT and a Bachelor's degree from The Cooper Union for the Advancement of Science and Art, showcasing a strong educational foundation in the field of biotechnology.

Work Experience 

NewCo

  • …

    2023 - Current

C

CCRM

  • Innovation and Technology Advisory group (ITAG)

    2022

    CCRM is a not-for-profit, public-private consortium supporting the development of foundational technologies that accelerate the commercialization of cell and gene therapies, and regenerative medicine technologies.

AB

Arbor Biotechnologies

  • Independent Board Member

    2021

Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.

Raised $230,600,000.00 from TCG Crossover, ArrowMark Partners, Ally Bridge Group, Logos Capital, Tao Capital Partners, ARCH Venture Partners, Tekla Capital Management, Surveyor Capital, Deep Track Capital and Vertex Pharmaceuticals.

arbor.bio
TR

Third Rock Ventures

  • Venture Partner

    2021 - 2023

    - CGT: company creation (2), series A (Cargo Tx)

GB

Generation Bio

  • Chief Operating Officer and founder

    2016 - 2021

Generation Bio is a biotechnology company that develops genetic medicines to treat genetic disorders.

Raised $536,400,000.00 from Moderna.

generationbio.com
bb

bluebird bio

  • SVP, Pharmaceutical Sciences

    2012 - 2016

    - Member of Leadership Team - Responsible for development, manufacturing, and operations; franchise lead for rare diseases - Skysona, Zynteglo, Abecma, and Lyfgenia

Bluebird Bio is a biopharma company that develops and commercializes gene therapies for the treatment of severe genetic diseases and cancer.

Raised $3,436,600,000.00 from Hercules Capital.

bluebirdbio.com

Baxter (former Archemix)

  • Sr. Director, Research and Development; Site Head-Cambridge

    2008 - 2012

    - Lead all R&D (res., cmc, dmpk, tox, quality) and Operation functions for the Cambridge, MA site - Transferred with the acquisition of Archemix hemophilia assets - Led diligence for gene therapy assets (resulted in Chatham Tx acquisition)

MP

Momenta Pharmaceuticals

  • Senior Director, Process Development and Manufacturing

    2007 - 2008

    - Managed validation and regulatory responses for enoxaparin (Lovenox) ANDA approval. - Lead dev. & manufacturing for glatiramir acetate (Copaxone) ANDA. Primary author on ANDA.

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.

Raised $88,500,000.00 from Atlas Venture, Mithra Ventures, Cardinal Partners, MVM Life Science Partners and Polaris Partners.

momentapharma.com
MP

Millennium Pharmaceuticals

  • Associate Director, Process Development

    2002 - 2006

Education 

Articles About Mark

Relevant Websites